论文部分内容阅读
目的 本文就以氦氧混合气 (79%氦 - 2 1%氧 )为驱动气源雾化吸入 β2 受体激动剂对支气管哮喘的治疗作用进行探讨。方法 选择门诊 2 4例轻中度支气管哮喘患者 ,随机分为治疗组 (13例 ,以氦氧混合气为驱动气源 )和对照组 (11例 ,以压缩空气为驱动气源 )雾化吸入备劳特 ,观察治疗前后肺功能的变化 ;选择病房 8例重症支气管哮喘患者采用自身对照方式 ,观察以氦氧混合气为驱动气源和以压缩空气为驱动气源雾化吸入备劳特前后肺功能和血气分析的变化。结果 门诊哮喘患者治疗组与对照组比较除PEF有显著性差异外 ,主要肺功能指标无统计学意义 ;病房重症哮喘患者以氦氧混合气为驱动气源与以压缩空气为驱动气源疗效比较 ,FVC、FEV1 0 、FEF50 差异具有显著性意义 ,血气分析结果示PaO2 差异具有显著性差异 ,PaCO2 有下降趋势。结论 氦氧混合气与雾化吸入β2 受体激动剂在治疗重症支气管哮喘方面与传统方法比较有明显优势 ,提示二者有良好的治疗协同作用
Objective To investigate the therapeutic effect of inhalation of β2 agonist on the bronchial asthma by helium-oxygen mixed gas (79% helium-21% oxygen). Methods Twenty-four patients with mild-to-moderate bronchial asthma were selected and randomly divided into treatment group (n = 13 with helium-oxygen mixture as driving gas source) and control group (n = 11 with compressed air as driving gas source) Before and after treatment, we observed the change of pulmonary function before and after treatment. Eight patients with severe bronchial asthma were selected as control by self-control method. Hemorrhagic gas mixture was used as the driving source and compressed air Changes in lung function and blood gas analysis. Results Compared with the control group, there was no significant difference in the main pulmonary function indexes between the outpatient asthma patients and the control group. The patients with severe asthma in the ward were treated with helium-oxygen mixture as the driving source and compressed air as the driving source , FVC, FEV1 0 and FEF50. The results of blood gas analysis showed significant differences in PaO2 and PaCO2 in declining trend. Conclusion Helic-oxygen mixture and inhaled β2 agonists have obvious advantages in the treatment of severe bronchial asthma compared with the traditional methods, suggesting that the two have good therapeutic synergies